文献速递免疫规划传染病防控与疫情报告

鼻内接种蛋白体疫苗对肺炎链球菌定植提供强保护

Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization.
PubMed 文献 · Vaccine · 2021-10-23

本研究以小鼠为模型,鼻内接种由肺炎链球菌抗原组成的蛋白体(PBs),评估其对鼻咽部定植的保护效果。结果显示,含PspAα的PBs较可溶性PspAα提供更强保护,且 conserved 抗原PBs单用或联用均减少定植,表明PBs可诱导强黏膜免疫与保护。

要点

  • PBs含高浓度抗原、稳定、耐蛋白酶且成本低,适合疫苗制剂。
  • 鼻内接种PspAα PBs对肺炎链球菌定植的保护优于可溶性PspAα。
  • 保守抗原PBs单抗原或多抗原配方均减少小鼠肺炎链球菌定植。

核心结论

  • 蛋白体(PBs)疫苗制剂可诱导强黏膜免疫应答和对肺炎链球菌定植的保护。

研究设计与样本

  • 小鼠鼻内接种由肺炎链球菌抗原组成的PBs,评估对鼻咽部定植的保护。

主要发现

  • PBs含高浓度抗原、稳定、相对耐蛋白酶、缓慢释放抗原且制造成本低。
  • PspAα PBs对肺炎链球菌定植的保护优于可溶性PspAα。
  • 可溶性蛋白与PBs免疫后,抗体结合肺炎链球菌及体内刺激后的鼻细胞因子谱存在差异。
  • 保守推定肺炎链球菌抗原PBs单抗原或多抗原配方均减少小鼠定植。

临床怎么用

  • PBs平台有望用于开发下一代黏膜疫苗,但当前证据仅来自小鼠模型。

局限性

  • 研究仅在小鼠中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations of antigen, are stable and relatively resistant to proteases, release antigen slowly and are cost-effective to manufacture. Yet, the capacity of PBs to provoke immune responses and protection in the upper respiratory tract, a major entry route of respiratory pathogens, is largely unknown. In this study, we vaccinated mice intranasally with PBs comprising antigens from Streptococcus pneumoniae and evaluated the level of protection against nasopharyngeal colonization. PBs composed of the α-helical domain of pneumococcal surface protein A (PspAα) provided superior protection against colonization with S. pneumoniae compared to soluble PspAα. Immunization with soluble protein or PBs induced differences in antibody binding to pneumococci as well as a highly distinct antigen-specific nasal cytokine profile upon in vivo stimulation with inactivated S. pneumoniae. Moreover, immunization with PBs composed of conserved putative pneumococcal antigens reduced colonization by S. pneumoniae in mice, both as a single- and as a multi-antigen formulation. In conclusion, PBs represent a vaccine formulation that elicits strong mucosal immune responses and protection. The versatility of this platform offers opportunities for development of next-generation vaccine formulations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Beek LF, Langereis JD, van den Berg van Saparoea HB, et al. Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization. Vaccine. 2021. PMID: 34696934. doi:10.1016/j.vaccine.2021.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。